Sun Pharmaceutical Industries Ltd.
Acme Plaza, Andheri - Kurla Road,
Andheri (East), Mumbai - 400 059, INDIA.
Tel. : (91-22) 2823 0102, 2821 2128, 6696 9696, 6696 9600
Fax : (91-22) 2821 2010
www.sunpharma.com
CIN : L24230GJ1993PLC019050

April 1, 2015

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited.,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Sub: Settlement of litigation for generic Angiomax® in US

This is to inform you that Sun Pharmaceutical Industries Ltd., and certain of our subsidiaries have executed a Settlement Agreement with 'The Medicines Company, USA' settling the lawsuit filed in the United States against the Company and its subsidiaries regarding submission of an Abbreviated New Drug Application (ANDA) by one of our subsidiaries, for a generic version of Angiomax®, Bivalirudin injection. This product is a direct thrombin inhibitor indicated for use as an anticoagulant.

Under the terms of the settlement agreement, the Company's subsidiary is entitled to launch its version of generic Angiomax® in the United States on June 30, 2019 or earlier under certain limited circumstances.

Further the agreement is subject to customary regulatory review.

This is for your information and record.

Thanking you,

Yours faithfully,
For **Sun Pharmaceutical Industries Ltd**

Ashok I. Bhuta
Compliance Officer

Angiomax® is the registered trademark of The Medicines Company, USA.